Pharmaceutical company · BAYRY

Bayer
clinical trial
pipeline

Registry checked

Published

Oncology is the largest mapped primary therapeutic group, with 26 of 99 active trials. This ranking covers mapped groups only. Finerenone is linked to 11 distinct active studies, with 4 Phase 3, 7 without a recorded phase. Darolutamide is linked to 4 distinct active studies, with 1 Phase 2, 2 Phase 3, 1 Phase 4.

40 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

99active trials
as lead sponsor
  • Phase 114
  • Phase 217
  • Phase 311
  • Phase 43
  • Phase not recorded54

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

2920 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later

2027-03 (estimated)2028-10 (estimated)
Mar 2027Oct 2028

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

NCT06944522 · ClinicalTrials.gov
Recorded by ComplyRx
31 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-021000011
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060010011
2026-10-070000000
2026-10-081010021
2026-10-090000000
2026-10-100000221
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140110022
2026-10-150110022
2026-10-160010011
2026-10-170100011
2026-10-180000000
2026-10-190000000
2026-10-202110042
2026-10-210300033
2026-10-221100021
2026-10-230000000
2026-10-240100011
2026-10-250000000
2026-10-261110031
2026-10-270000000
2026-10-280020022
2026-10-290000000
2026-10-300000000
2026-10-310100121
Type totals6119032920 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Finerenone

Canonical investigational asset

11
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 34
  • Phase 40
  • Phase not recorded7
Studied condition
Children · Chronic Heart Failure · Chronic Kidney Disease
Next primary completion
10 April 2027 · estimated
Open drug

Darolutamide

nubeqa

4
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 21
  • Phase 32
  • Phase 41
  • Phase not recorded0
Studied condition
Biochemically Recurrent Prostate Cancer · Cancer · High-risk Localized Prostate Cancer
Next primary completion
30 July 2027 · estimated
Open drug

Acoramidis

ATTRUBY

3
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded2
Studied condition
Transthyretin Amyloid Cardiomyopathy · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Next primary completion
Not reported
Open drug

Sevabertinib

hyrnuo

2
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Non-small Cell Lung Cancer, HER2 Mutation · Advanced Solid Tumors · HER2 Mutation
Next primary completion
28 October 2027 · estimated
Open drug

AB-1005

Canonical investigational asset

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Parkinson Disease · PARKINSON DISEASE (Disorder)
Next primary completion
Not reported
Open drug

Radium-223 dichloride

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Next primary completion
Not reported
Open drug

50 of 99 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 50 of 99 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Bayer trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
FIONA
Finerenone

NCT05196035

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

4 candidate observations · 2 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

2 inspected observations omitted. At most three verified observations are shown, not full history.

  • status flip · Recorded 2026-08-20 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • pc date moved · Recorded 2026-08-20 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 28 Mar 2022 · actual
Primary completion: 10 Apr 2027 · estimated
Study completion: 10 May 2027 · estimated

2021202220232024202520262027202820292030
ARASTEP
Darolutamide

NCT05794906

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

4 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 03 Apr 2023 · actual
    Primary completion: 30 Jul 2027 · estimated
    Study completion: 29 Mar 2030 · estimated

    2021202220232024202520262027202820292030
    SOHO-02
    Sevabertinib

    NCT06452277

    Phase 3 · Recruiting

    Trial source and qualifications

    A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    5 candidate observations · 2 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

    • enrollment change · Recorded 2026-09-24 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-10-15 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 28 Aug 2024 · actual
    Primary completion: 28 Oct 2027 · estimated
    Study completion: 27 Jun 2029 · estimated

    2021202220232024202520262027202820292030
    ASSESS
    BAY 3401016

    NCT07211685

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

    • pc date moved · Recorded 2026-08-20 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • status flip · Recorded 2026-09-19 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 19 Nov 2025 · actual
    Primary completion: 29 Nov 2027 · estimated
    Study completion: 29 Nov 2027 · estimated

    2021202220232024202520262027202820292030
    A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies
    Regorafenib

    NCT06246643

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 24 Jan 2024 · actual
      Primary completion: 27 Apr 2028 · estimated
      Study completion: 27 Apr 2028 · estimated

      2021202220232024202520262027202820292030
      PIA
      AB-1005

      NCT07215403

      Phase 2 · Not yet recruiting

      Trial source and qualifications

      Open-Label, Multi-Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: Nov 2026 · estimated
        Primary completion: 30 Apr 2028 · estimated
        Study completion: 01 Nov 2028 · estimated

        2021202220232024202520262027202820292030

        Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

        6 selected of 22 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 5 actual primary completions, 0 untyped primary completions, 1 past estimates, 0 outside the horizon, 0 contradictory dates.

        04 / Therapeutic focus

        Where the activity is

        26

        active trials in Oncology

        Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

        Active trials by primary therapeutic area

        • Oncology26 trials
        • Cardiovascular13 trials
        • Metabolic/Endocrine/Nutrition7 trials
        • Neurology6 trials
        • Renal & Urology3 trials
        • Womens Health2 trials
        • Infectious Disease1 trials
        • Ophthalmology1 trials
        • Unmapped40 trials
        • Healthy volunteers0 trials

        Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

        06 / Related companies

        All companies
        A

        AstraZeneca

        Shared indexed programme context · 1 selected asset

        Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

        Sources, scope and methodology

        ClinicalTrials.gov lead-sponsor scope

        Canonical current-owner attribution covers 1,694 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Bayer. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

        ClinicalTrials.gov

        Attribution coverage

        1,694 distinct registry candidates produced 1,694 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

        Indexed enrichment

        1,192 scoped records have indexed enrichment and 502 do not. Missing enrichment does not remove a trial from cohort counts.

        Scope observation

        The successful attribution check completed at 2026-11-01T03:08:33.540Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 26d3df1f8d104f4561b0cc66f69391f40be5e674000dcd078ba2c48086936792.

        Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

        Dated canonical-attribution snapshot: 1,694 mapped lead-sponsored clinical studies across all statuses. 1,192 have indexed enrichment, 502 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

        Keep following
        what matters.

        Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

        Build your watch

        Choose what to track in the watch builder.